Muhammet Ozer

Sharing our ASCO Daily News piece on #KRAS G12C–mutant #CRC, focused on combination therapies & addressing resistance. 🚀 #ASCODailyNews @ASCO @TimothyJBrownMD @utswcancer dailynews.ascopubs.org/do/beyond-mono…

Presenting at #GI26 @ASCO. Honored to receive a @ConquerCancerFd Merit Award🎖️. Phase II study of ATRA + atezolizumab + bevacizumab in refractory MSS #mCRC. Manageable, mostly low-grade #AEs. Efficacy data forthcoming🎢 | Great mentorship from @SyedKazmiMD @utswcancer

HER2 discordance in UGI cancers 🙅‍♂️Got lots of foot traffic and interesting questions 🧐 Manuscript in progress 📝 Great leadership from the idea man @TimothyJBrownMD 🤠. @TheGutOncLab. @UTSWHemeOnc @MuhammetOzerMD @UGrewalMD